Aug 11, 2022 – Our 20th Japanese profile has just been uploaded
The National Cancer Registry (NCR) commenced operations in January 2016. Accurate nationwide data obtained from NCR contribute to the planning and evaluation of cancer control in Japan. This database is utilized in evaluating the quality of medical care for cancer patients, in assessing the accuracy of cancer screening, and in follow-up surveys in nationwide cohort studies.
National Cancer Registry (Japan)
Database Contact Data
Please complete the contact form (in Japanese or English) at - https://reg18.smp.ne.jp/regist/is?SMPFORM=ndqe-lfogsa-3b8c6f3d580c85ee376b1c4fd94627fa
Alternate Contact
National Cancer Center of Japan can be contacted via the form on this page:
https://ganjoho.jp/med_pro/cancer_control/can_reg/national/datause/index.html
References of Studies Using/Describing Database
1. Nakata K, Matsuda T, Hori M, Sugiyama H, Tabuchi K, Miyashiro I, Matsumoto K, Yoneda A, Takita J, Shimizu C, Katanoda K. Cancer incidence and type of treatment hospital among children, adolescents, and young adults in Japan, 2016-2018. Cancer Sci. 2023 Sep;114(9):3770-3782.
2. Ogata D, Namikawa K, Nakano E, Fujimori M, Uchitomi Y, Higashi T, Yamazaki N, Kawai A. Epidemiology of skin cancer based on Japan's National Cancer Registry 2016-2017. Cancer Sci. 2023 Jul;114(7):2986-2992.
3. Matsumoto H, Kobayashi N, Shinoda S, Goto A, Kaneko A, Fukuda N, Kamimaki C, Kubo S, Watanabe K, Horita N, Hara Y, Ishikawa Y, Kaneko T. Regional differences in epidermal growth factor receptor-tyrosine kinase inhibitor therapy in lung cancer treatment using a national database in Japan. Sci Rep. 2023 Mar 30;13(1):5208.
4. Katanoda K, Ito H, Ito Y, Katayama K, Nishino Y, Tsutsui A, Togawa K, Tanaka H, Ohno Y, Nakaya T. [Geographic information in National Cancer Registry data: Overseas examples and challenges in Japan]. Nihon Koshu Eisei Zasshi. 2023 Mar 23;70(3):163-170. Japanese.
5. Kurisu K, Fujimori M, Harashima S, Akechi T, Matsuda T, Saika K, Yoshiuchi K, Miyashiro I, Uchitomi Y. Suicide, other externally caused injuries, and cardiovascular disease within 2 years after cancer diagnosis: A nationwide population-based study in Japan (J-SUPPORT 1902). Cancer Med. 2023 Feb;12(3):3442-3451.
6. Makiuchi T, Sobue T. Descriptive epidemiology of biliary tract cancer incidence and geographic variation in Japan. Eur J Cancer Prev. 2023 Jan 1;32(1):2-9.
7. Satake T, Morizane C, Rikitake R, Iwata S, Hirano H, Ogata D, Shimoi T, Sudo K, Yoshimoto S, Yamazaki N, Katoh Y. O12-2 The epidemiology of rare cancers from National Cancer Registry in Japan. Annals of Oncology. 2022 Jul 1;33:S473-4.
8. Kobayashi N, Oike T, Kubo N, Miyasaka Y, Mizukami T, Sato H, Adachi A, Katoh H, Kawamura H, Ohno T. Colorectal Cancer Screening Outcomes of 2412 Prostate Cancer Patients Considered for Carbon Ion Radiotherapy. Cancers (Basel). 2021 Sep 6;13(17):4481.
9. Okuyama A, Tsukada Y, Higashi T. Coverage of the hospital-based cancer registries and the designated cancer care hospitals in Japan. Jpn J Clin Oncol. 2021 May 28;51(6):992-998.
10. Yoshida M, Yabuuchi Y, Kakushima N, Kato M, Iguchi M, Yamamoto Y, Kanetaka K, Uraoka T, Fujishiro M, Sho M; Japan Duodenal Cancer Guideline Committee. The incidence of non-ampullary duodenal cancer in Japan: The first analysis of a national cancer registry. J Gastroenterol Hepatol. 2021 May;36(5):1216-1221.
July 5, 2022: The Swedish Multiple Sclerosis Registry profile has just been added
Active since 2001, the Swedish MS Registry (SMSreg) is a government-funded quality register designed to ensure optimal health care for patients with multiple sclerosis (MS). All Swedish neurology departments are users and providers of data, and currently more than 14,000 patients with MS have been registered.
Swedish Multiple Sclerosis Registry (Sweden) **
Database Contact Data
Prof. Jan Hillert
Karolinska University Hospital
17176 Stockholm
SWEDEN
Email: jan.hillert@ki.se
Alternate Contact
1. Anna Cunningham (Multiple Sclerosis)
Email: anna.cunningham@regionstockholm.se
2. Email - info@neuroreg.se
References of Studies Using/Describing Database
1. Svenningsson A, Frisell T, Burman J, Salzer J, Fink K, Hallberg S, Hambraeus J, Axelsson M, Nimer FA, Sundström P, Gunnarsson M, Johansson R, Mellergård J, Rosenstein I, Ayad A, Sjöblom I, Risedal A, de Flon P, Gilland E, Lindeberg J, Shawket F, Piehl F, Lycke J. Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial. Lancet Neurol. 2022 Aug;21(8):693-703.
2. Spelman T, Forsberg L, McKay K, Glaser A, Hillert J. Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry. Mult Scler. 2022 Jun;28(7):1051-1059.
3. Manouchehrinia A, Kingwell E, Zhu F, Tremlett H, Hillert J, Ramanujam R. A multiple sclerosis disease progression measure based on cumulative disability. Mult Scler. 2021 Oct;27(12):1875-1883.
4. Landtblom AM, Berntsson SG, Boström I, Iacobaeus E. Multiple sclerosis and COVID-19: The Swedish experience. Acta Neurol Scand. 2021 Sep;144(3):229-235.
5. Hedström AK, Hillert J, Brenner N, Butt J, Waterboer T, Strid P, Kockum I, Olsson T, Alfredsson L. DRB1-environment interactions in multiple sclerosis etiology: results from two Swedish case-control studies. J Neurol Neurosurg Psychiatry. 2021 Jul;92(7):717-722.
6. Stenberg E, Forsberg L, Hedström A, Hillert J, Näslund E. Bariatric and metabolic surgery in patients with morbid obesity and multiple sclerosis - a nationwide, matched cohort study. Surg Obes Relat Dis. 2021 Jun;17(6):1108-1114.
7. Kågström S, Fält A, Berglund A, Piehl F, Olsson T, Lycke J. Reduction of the risk of PML in natalizumab treated MS patients in Sweden: An effect of improved PML risk surveillance. Mult Scler Relat Disord. 2021 May;50:102842.
8. McKay KA, Friberg E, Razaz N, Alexanderson K, Hillert J. Long-term Socioeconomic Outcomes Associated With Pediatric-Onset Multiple Sclerosis. JAMA Neurol. 2021 Apr 1;78(4):478-482.
9. Hillert J, Magyari M, Soelberg Sørensen P, Butzkueven H, Van Der Welt A, Vukusic S, Trojano M, Iaffaldano P, Pellegrini F, Hyde R, Stawiarz L, Manouchehrinia A, Spelman T. Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network. Front Neurol. 2021 Mar 17;12:647811.
10. Alping P, Burman J, Lycke J, Frisell T, Piehl F. Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis. Neurology. 2021 Mar 16;96(11):e1574-e1584.
Cerner Enviza Cancerology (France)
Database Contact Data
Patricia Medina
Cerner Enviza
Email: Patricia.Medina@cernerenviza.com
Alternate Contact
1. Cécile Pacheco
Cerner Enviza
Email: Cecile.Pacheco@cernerenviza.com
2. If you cannot reach the database manager, you may contact the company by completing the contact form at: https://www.oracle.com/life-sciences/contact-us/
References of Studies Using/Describing Database
1. Weisel K, Wadlund AO, Gungor G, Dergarabetian E, Pacheco C, Masurkar N, Rodriguez-Otero P. Real-world study on adoption of standard-of-care for transplant-eligible newly diagnosed multiple myeloma patients between 2017 and 2020/2021 across France, Germany, Spain, and Italy. Eur J Haematol. 2022 Oct;109(4):388-397.
2. E. Manna, K. Kikuchi , H. Chalubert , I. Amri, P. Medina. BRAF mutation testing and results among French patients with solid tumours. Poster presented at ESMO 2020.
3. Bassila L, Medina P, Chalubert H. Trends in anti-emetic drug use in hematology-oncology based on Cancerology data in France. Poster presented at ISPOR US 2020.
4. Chabernaud H, Descoins S, Flinois A, Real-world studies in Onco-hematology: which parameter should be used to measure the efficacy of treatments. Poster presented at ISPOR EU 2019.
5. Medina P, Chalubert H, Pezic N, Wiegand J, Brihaye H, Spitzer M. PCN147 Epidemiologic burden of pulmonary metastasis in France. Value in Health. 2019 May 1;22:S84.
6. Colomer R, Hall P, Szkultecka-Debek M, Bondi RC, Flinois A, Auziere S, Le Cléac'h JY. Real-world treatment in patients with HER2+ metastatic breast cancer: Treatment decisions in HER2+ mBC. Breast Cancer Res Treat. 2018 Feb;168(1):197-205.
7. Klein AB, Wang H, Shire N, Chalubert H, Alessandrini ER, Descoins S, Medina P. Treatment Patterns In Head & Neck Squamous Cell Cancer In France: Artiste Study on Cancerology Patient Charts. Value in Health. 2017 Oct 1;20(9):A419.
8. Chabernaud H, Bonnelye G, Flinois A, French physician sensitivity to and consideration of the costs of cancer treatment. Poster presented at ISPOR EU 2015.
9. Flinois A, Bonnelye G, Chabernaud H, Evolution of the number of patients treated for metastatic cancer between 2003 and 2013 in France. Poster presented at ISPOR EU 2015.
Jun 17, 2022: Our 370th profile is the Japan Nurses’ Health Study
Initiated in 2001, the Japan Nurses’ Health Study (JNHS) is a prospective cohort investigation of the effects of lifestyle and healthcare on women’s health.
Japan Nurses’ Health Study (Japan)
Database Contact Data
Principal Investigator -
Kunihiko Hayashi, PhD
Executive Director of Education and Evaluation
Vice-President, Gunma University
4-2 Aramaki
Maebashi
Gunma 371-8510
JAPAN
Phone: (+81) 27-220-7112
Fax: (+81) 27-220-7535
Email: khayashi@gunma-u.ac.jp
Alternate Contact
Email: jnhs.jimu@gmail.com
References of Studies Using/Describing Database
1. Chung HF, Dobson AJ, Hayashi K, Hardy R, Kuh D, Anderson DJ, van der Schouw YT, Greenwood DC, Cade JE, Demakakos P, Brunner EJ, Eastwood SV, Sandin S, Weiderpass E, Mishra GD. Ethnic Differences in the Association Between Age at Natural Menopause and Risk of Type 2 Diabetes Among Postmenopausal Women: A Pooled Analysis of Individual Data From 13 Cohort Studies. Diabetes Care. 2023 Nov 1;46(11):2024-2034.
2. Yasui T, Ideno Y, Nagai K, Hayashi K. Characteristics of HRT users in Japan: Evidence from the Japan Nurses’ Health Study. Maturitas. 2023 Jul;173:1-6.
3. Otsuka E, Miyazaki Y, Ideno Y, Nagai K, Kobayashi A, Kishi M, Lee JS, Hayashi K. Validity of a 98-item Food Frequency Questionnaire for the Japan Nurses’ Health Study. The Kitakanto Medical Journal. 2023;73(4):277-283. Medical*Online
4. Liang C, Chung HF, Dobson AJ, Hayashi K, van der Schouw YT, Kuh D, Hardy R, Derby CA, El Khoudary SR, Janssen I, Sandin S, Weiderpass E, Mishra GD. Infertility, recurrent pregnancy loss, and risk of stroke: pooled analysis of individual patient data of 618 851 women. BMJ. 2022 Jun 22;377:e070603.
5. Hayashi K, Ideno Y, Nagai K, Lee JS, Yasui T, Kurabayashi T, Takamatsu K. Complaints of reduced cognitive functioning during perimenopause: a cross-sectional analysis of the Japan Nurses’ Health Study. Womens Midlife Health. 2022 Jun 5;8(1):6.
6. Yasui T, Ideno Y, Shinozaki H, Kitahara Y, Nagai K, Hayashi K. Prevalence of the Use of Oral Contraceptives and Hormone Replacement Therapy in Japan: The Japan Nurses' Health Study. J Epidemiol. 2022 Mar 5;32(3):117-124.
7. Katanoda K, Ideno Y, Maruoka N, Nagai K, Tsukada Y, Matsuki M, Higashi T, Hayashi K. Validation of Identifying Cancer Diagnosis Based on Self-Reported Information in the Japan Nurses' Health Study. Asian Pac J Cancer Prev. 2022 Feb 1;23(2):651-657.
8. Kishi M, Ideno Y, Nagai K, Lee JS, Suzuki S, Hayashi K. Use of Dietary Supplements among Japanese Female Nursing Professionals. J Nutr Sci Vitaminol (Tokyo). 2022;68(3):213-220.
9. Nagai K, Homma Y, Ideno Y, Hayashi K. Prevalence and factors associated with overactive bladder and stress urinary incontinence in the Japan Nurses' Health Study. Menopause. 2021 Dec 13;29(2):129-136.
10. Ri M, Hayashi K, Kurabayashi T, Lee JS, Ideno Y, Nagai K, Yasui T, Kubota T, Takamatsu K. Hypertensive disorders of pregnancy increase the risk of future menopausal hot flashes in Japanese women: results from the Japan Nurses' Health Study. Menopause. 2021 Oct 25;29(2):164-169.